[A population-based epidemiological survey of neonatal respiratory failure in Huai'an City of Jiangsu Province, in 2010]

Zhongguo Dang Dai Er Ke Za Zhi. 2014 Nov;16(11):1138-42.
[Article in Chinese]

Abstract

Objective: To investigate the prevalence, clinical characteristics, treatment, and prognosis of neonatal respiratory failure (NRF) in Huai'an, Jiangsu Province, China, in 2010.

Methods: The clinical data of all NRF cases in the hospitals of Huai'an in 2010 were prospectively collected and analyzed using descriptive epidemiological methods.

Results: Among 60,986 live births in Huai'an in 2010, there were 556 (0.91%) cases of NRF. The average birth weight of newborns with NRF was 2,433±789 g, with 53.8% determined as low birth weight and 64.1% as preterm. The major causes of NRF were respiratory distress syndrome, pneumonia, asphyxia, sepsis, and pulmonary hemorrhage. Among the newborns with NRF, 23.7% were accompanied by certain birth defects. Fourteen percent of newborns with NRF received pulmonary surfactant (PS) therapy, and the median time of the first dose of PS was 5 hours (range: 0-51 hours). Nasal continuous positive airway pressure treatment, conventional mechanical ventilation, and high-frequency ventilation were used in 67.9%, 33.3%, and 13.7% of patients, respectively. The cure and improvement rate of NRF patients was 73.9% (411/556), and the mortality rate was 22.5% (125/556). The average hospitalization expenses were 9,270 (range: 196-38182) Yuan.

Conclusions: High morbidity, high mortality and high medical costs make NRF a serious challenge in Huai'an. It is essential to improve the quality of perinatal care and develop new techniques and new models in neonatal respiratory therapy in order to reduce the morbidity and mortality of NRF.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • China / epidemiology
  • Female
  • Humans
  • Infant, Newborn
  • Male
  • Pulmonary Surfactants / therapeutic use
  • Respiration, Artificial
  • Respiratory Insufficiency / epidemiology*
  • Respiratory Insufficiency / mortality
  • Respiratory Insufficiency / therapy
  • Time Factors
  • Treatment Failure

Substances

  • Pulmonary Surfactants